company background image
PKTX

ProtoKinetix OTCPK:PKTX Stock Report

Last Price

US$0.03

Market Cap

US$9.7m

7D

0%

1Y

-55.9%

Updated

27 Jan, 2023

Data

Company Financials

ProtoKinetix, Incorporated

OTCPK:PKTX Stock Report

Mkt Cap: US$9.7m

PKTX Stock Overview

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).

PKTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

ProtoKinetix, Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ProtoKinetix
Historical stock prices
Current Share PriceUS$0.03
52 Week HighUS$0.083
52 Week LowUS$0.018
Beta0.12
1 Month Change-9.09%
3 Month Change-15.61%
1 Year Change-55.88%
3 Year Change-83.33%
5 Year Change-53.16%
Change since IPO650.00%

Recent News & Updates

Recent updates

Shareholder Returns

PKTXUS BiotechsUS Market
7D0%0.7%2.3%
1Y-55.9%7.1%-9.7%

Return vs Industry: PKTX underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: PKTX underperformed the US Market which returned -9.7% over the past year.

Price Volatility

Is PKTX's price volatile compared to industry and market?
PKTX volatility
PKTX Average Weekly Movement25.3%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: PKTX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: PKTX's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999n/aClarence Smithhttps://www.protokinetix.com

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases.

ProtoKinetix, Incorporated Fundamentals Summary

How do ProtoKinetix's earnings and revenue compare to its market cap?
PKTX fundamental statistics
Market CapUS$9.69m
Earnings (TTM)-US$1.72m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PKTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$1.72m
Earnings-US$1.72m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.0053
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PKTX perform over the long term?

See historical performance and comparison